Novel method for generating antibodies could revolutionize Parkinson's research

Researchers have developed a new method to generate antibodies that specifically target misfolded proteins involved in diseases like Parkinson’s and Alzheimer’s. These misfolded proteins clump together, forming toxic aggregates that damage brain cells—a process known as protein aggregation. Traditional methods struggle to study these protein aggregates because they are short-lived and structurally diverse. Antibodies, which can precisely bind to targets, are a powerful tool for investigating them, but producing antibodies against such unstable structures has been challenging. To overcome this, the new platform combines computational design and directed evolution to develop and screen antibodies for their ability to bind to or prevent aggregation. According to Francesco Aprile, PhD, from Imperial College London, this approach significantly speeds up the discovery and production process, saving time and resources. Using this platform, the researchers successfully created nanobodies—small, single-domain antibodies—that target amyloid-beta and alpha-synuclein, the key proteins linked to Parkinson’s disease. These nanobodies help reveal how these proteins form toxic structures and identify specific regions that could serve as therapeutic targets. This breakthrough could pave the way for new drug development strategies aimed at slowing or preventing neurodegenerative diseases.